Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00

New Survey Shows Shoppers Are Showing Up This Holiday Season — Even Amid Tariffs and Turmoil 17-07-2025, 19:00

University of Rochester’s Eastman School of Music Recognized in the QS World University Rankings 3-06-2024, 18:00